Machine Learning Approaches for Drug Combination Discovery
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
Drugs used in combination therapy has superior treatment efficacy. Preclinical experimental screenings have fueled this progress by identifying and prioritizing new candidate combinations, but they lack predictive power over the transcriptomic data of individualized cancer samples in which exploration of the combination treatment space is intractable. There is an unmet need for computational modeling approaches that can accurately predict personalized synergistic drug combinations by integrating patient-specific molecular data. To overcome this limitation, we developed PAIRWISE, a novel DL framework to survey large preclinical screening dataset for drug combination modeling. Our method showed improved drug synergy prediction compared with benchmarked methods with superior sensitivity/specificity in the prediction of likely synergy. To further investigate safety of drug combination, we developed DDI-GPT, innovated with blending knowledge graph into a sentence as an input in large language model, achieves precision and accuracy in drug-drug interaction prediction.